uteal phase support during frozen embryo transfer cycle
Phase 3
- Conditions
- Female infertility, unspecified.Female infertility, unspecified
- Registration Number
- IRCT201611011141N24
- Lead Sponsor
- Royan institute, Vice chancellor for research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
Patients with surplus embryos undergone infertility treatment cycles (e.g. OHSS, inadequate endometrium, surplus frozen embryo from any cause); Age 21-37 years; Normal BMI (18.5 Exclusion criteria: Endometrial thickness =7mm; Egg Donors; Surrogacy; Male factor infertility with azoospermia; Age <37 years old; Hydrosalpinx; Uterine anomalies; Myoma with a compression effect or submocusa myoma; PGD; Blastocyst embryo transfer, ZIFT and GIFT.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ongoing pregnancy rate. Timepoint: 6 & 12 weeks of pregnancy. Method of measurement: ultrasonography.
- Secondary Outcome Measures
Name Time Method Estrogen. Timepoint: start using progesterone for luteal support in FET cycle (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy. Method of measurement: Blood serum level.;Progesterone. Timepoint: start using progesterone for luteal support in FET cycle (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy. Method of measurement: Blood serum level.